Cargando…

Real-world experience of combined treatment with azacitidine and romidepsin in patients with peripheral T-cell lymphoma

Detalles Bibliográficos
Autores principales:	Kalac, Matko, Jain, Salvia, Tam, Constantine S., Xiao, Zhengrui, Montanari, Francesca, Kanakry, Jennifer, Huber, Bryan D., Goldfinger, Mendel, O’Connor, Owen A., Marchi, Enrica
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	The American Society of Hematology 2023
Materias:	Research Letter
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10368677/ https://www.ncbi.nlm.nih.gov/pubmed/36790924 http://dx.doi.org/10.1182/bloodadvances.2022009445

Ejemplares similares

P1195: A REAL WORLD EXPERIENCE OF COMBINED TREATMENT WITH ROMIDEPSIN AND AZACITIDINE IN PATIENTS WITH PERIPHERAL T-CELL LYMPHOMA.
por: Kalac, M., et al.
Publicado: (2022)

Romidepsin in the treatment of cutaneous T-cell lymphoma
por: Jain, Salvia, et al.
Publicado: (2011)

Romidepsin for the Treatment of Peripheral T-Cell Lymphoma
por: Barbarotta, Lisa, et al.
Publicado: (2015)

Long-Term Treatment with Romidepsin in Patients with Peripheral T-Cell Lymphoma
por: Irlé, Claudius, et al.
Publicado: (2016)

Immunosuppression-associated primary cutaneous plasmablastic lymphoma secondary to romidepsin
por: Costello, Collin M., et al.
Publicado: (2019)

Novel therapeutic agents for cutaneous T-Cell lymphoma
por: Jain, Salvia, et al.
Publicado: (2012)

Tolerability to romidepsin in patients with relapsed/refractory T-cell lymphoma
por: Foss, Francine, et al.
Publicado: (2014)

Responses to romidepsin by line of therapy in patients with relapsed or refractory peripheral T‐cell lymphoma
por: Foss, Francine, et al.
Publicado: (2016)

Successful response with romidepsin in relapsed peripheral T-cell lymphoma, not otherwise specified with leukemic progression
por: Sato, Shuku, et al.
Publicado: (2020)

N-quinoline-benzenesulfonamide derivatives exert potent anti-lymphoma effect by targeting NF-κB
por: Kalac, Matko, et al.
Publicado: (2020)

Multicenter phase 2 study of romidepsin plus lenalidomide for previously untreated peripheral T-cell lymphoma
por: Ruan, Jia, et al.
Publicado: (2023)

Romidepsin-induced neutrophilic urticaria
por: Scott, Brian, et al.
Publicado: (2016)

Romidepsin Used as Monotherapy in Sequence with Allogeneic Stem Cell Transplant in a Patient with Peripheral T-Cell Lymphoma
por: Finn, Nicholas, et al.
Publicado: (2014)

Romidepsin for the treatment of relapsed/refractory peripheral T-cell lymphoma: pivotal study update demonstrates durable responses
por: Coiffier, Bertrand, et al.
Publicado: (2014)

Romidepsin induces durable responses in patients with relapsed or refractory angioimmunoblastic T‐cell lymphoma
por: Pro, Barbara, et al.
Publicado: (2016)

CD19-Targeted Chimeric Antigen Receptor T-cell Therapy for Concomitant Diffuse Large B-cell Lymphoma and Multiple Myeloma
por: D'Ovidio, Tyler, et al.
Publicado: (2023)

Management of Hodgkin Lymphoma in a Sickle Cell Patient: A Case Report
por: Ashraf, Farah, et al.
Publicado: (2019)

Romidepsin: evidence for its potential use to manage previously treated cutaneous T cell lymphoma
por: Poligone, Brian, et al.
Publicado: (2011)

Complete response to romidepsin as monotherapy in treatment-resistant subcutaneous panniculitis-like T-cell lymphoma
por: Jothishankar, Balaji, et al.
Publicado: (2020)

BRENTUXIMAB VEDOTIN AND BENDAMUSTINE (BvB) IN PATIENTS WITH RELAPSED OR REFRACTORY HODGKIN LYMPHOMA: AN INTERNATIONAL, MULTICENTER, SINGLE-ARM, PHASE 1–2 TRIAL
por: O’Connor, Owen A., et al.
Publicado: (2018)

R-Loop–Mediated ssDNA Breaks Accumulate Following Short-Term Exposure to the HDAC Inhibitor Romidepsin
por: Safari, Maryam, et al.
Publicado: (2021)

Clinically significant responses achieved with romidepsin across disease compartments in patients with cutaneous T-cell lymphoma
por: Kim, Ellen J., et al.
Publicado: (2015)

Relief of intractable pruritus with romidepsin in patients with cutaneous T‐cell lymphoma: A series of four cases
por: Poligone, Brian, et al.
Publicado: (2019)

Pharmacokinetics and Immunological Effects of Romidepsin in Rhesus Macaques
por: Kleinman, Adam J., et al.
Publicado: (2020)

Romidepsin for the treatment of relapsed/refractory peripheral T cell lymphoma: prolonged stable disease provides clinical benefits for patients in the pivotal trial
por: Foss, Francine, et al.
Publicado: (2016)

Deciphering the molecular effects of romidepsin on germ cell tumours: DHRS2 is involved in cell cycle arrest but not apoptosis or induction of romidepsin effectors
por: Nettersheim, Daniel, et al.
Publicado: (2018)

A phase II study on the role of gemcitabine plus romidepsin (GEMRO regimen) in the treatment of relapsed/refractory peripheral T-cell lymphoma patients
por: Pellegrini, Cinzia, et al.
Publicado: (2016)

Erratum to: Romidepsin for the treatment of relapsed/refractory peripheral T cell lymphoma: prolonged stable disease provides clinical benefits for patients in the pivotal trial
por: Foss, Francine, et al.
Publicado: (2017)

Use of ifosfamide, carboplatin and etoposide in combination with brentuximab vedotin or romidepsin based on CD30 positivity in relapsed/refractory peripheral T‐cell lymphoma
por: Gentille, Cesar, et al.
Publicado: (2022)

The Depsipeptide Romidepsin Reverses HIV-1 Latency In Vivo
por: Søgaard, Ole S., et al.
Publicado: (2015)

Generation of pralatrexate resistant T‐cell lymphoma lines reveals two patterns of acquired drug resistance that is overcome with epigenetic modifiers
por: Scotto, Luigi, et al.
Publicado: (2020)

Low dose continuous lenalidomide in heavily pretreated patients with relapsed or refractory classical Hodgkin lymphoma: a retrospective case series
por: Ma, Helen, et al.
Publicado: (2020)

A5 Peripheral blood cells contribute to HIV-1 viremia induced by romidepsin
por: Winckelmann, A., et al.
Publicado: (2017)

The histone deacetylase inhibitor romidepsin synergizes with lenalidomide and enhances tumor cell death in T-cell lymphoma cell lines
por: Cosenza, Maria, et al.
Publicado: (2016)

Successful Treatment of a Patient with Brentuximab Vedotin-Refractory ALK-Negative Anaplastic Large Cell Lymphoma with Romidepsin
por: Jo, Tatsuro, et al.
Publicado: (2020)

Romidepsin targets multiple survival signaling pathways in malignant T cells
por: Valdez, B C, et al.
Publicado: (2015)

Synergistic Effect of Simvastatin and Romidepsin on Gamma-globin Gene Induction
por: Habibi, Hussain, et al.
Publicado: (2019)

Simvastatin-romidepsin combination kills bladder cancer cells synergistically
por: Okubo, Kazuki, et al.
Publicado: (2021)

Electrocardiographic effects of class 1 selective histone deacetylase inhibitor romidepsin
por: Sager, Philip T, et al.
Publicado: (2015)

Use of class I histone deacetylase inhibitor romidepsin in combination regimens
por: Petrich, Adam, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_qmrcfrrt0jae0uj8fhn2i61shh